You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    SBC: TheraTarget, Inc.            Topic: 102

    SUMMARY This STTR Phase II proposal addresses the significant need for improved treatment options for patients with liver cancerthe fifth highest incidence of cancer in the worldBecause of the lack of symptomshepatocellular carcinomaHCCis detected at advanced stages inof casesfor which theyear survival rate isand atyears it isThe only curative option for advanced HCC is surgical liver resection an ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    AbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development of user-friendly fluorescence based assays for marine toxins

    SBC: SeaTox Research Inc            Topic: 113

    ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Microfluidic Nitric Oxide Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    PROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms

    SBC: TheraTarget, Inc.            Topic: 106

    NARRATIVE This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymerSELPsilk elastinlike proteinKto embolize cerebral aneurysmsThe SELP embolic would reduce the risk of aneurysm rupture while minimizing the risk of recanalization after treatment and providing a platform for del ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a novel therapy for diabetic retinopathy

    SBC: Everglades Biopharma, LLC            Topic: W

    Project Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Self expanding hydrogel for pelvic brachytherapy a novel method for vaginal packing and customized radiation therapy

    SBC: BrachyFoam, LLC            Topic: 102

    This proposal aims to develop a polymer hydrogel strategy that can be used to improve the clinical care of patients receiving brachytherapy for gynecological cancers The biocompatible hydrogel will form in situ after being injected into the vaginal space and later removed by instillation of water to soften the hydrogel for easy extraction This Phase I proposal focuses on optimizing the polymer ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. HELical Biodegradable Photochemical(HELP)Stents for AVF Maturation

    SBC: Inovasc, LLC            Topic: 300

    ABSTRACT Although arteriovenous fistulae AVFs are the preferred mode of dialysis vascular access over fail to mature in that they do not develop an adequate blood flow or diameter to support hemodialysis This results in a very significant clinical morbidity and economic cost At a pathogenetic level AVF maturation failure is due to a small vessels b bad non laminar hemodynamic pr ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government